ClinicalTrials.gg
Active, not recruitingNCT06868654DREAMM 7Updated Apr 23, 2026Results posted

China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 3 interventional study of Belantamab mafodotin and Daratumumab in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 7 months after the study started (first participant enrolled Jul 2021, registered Mar 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
18th of 49
72 · median 50
Started
2021
with 10 others
Phase 3
9 of 49
2 open now
Primary completion
2024-04
later than 3 of 34 live
Registered
36th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 18th largest by enrollment, is one of 11 that started in 2021, is one of 9 in phase 3, reaches primary completion later than 3 of the 34 other live ones, and was the 36th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with relapsed/refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • China Subpopulation
  • Belantamab mafodotin
  • Relapsed/refractory multiple myeloma
  • Daratumumab
  • Bortezomib
  • Dexamethasone
  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy and must have documented disease progression during or after their most recent therapy.
  • (ECOG) performance status of 0 to 2.
  • Must have at least 1 aspect of , defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (\<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [] version 5.0) must be \<=Grade 1 at the time of enrollment, except for alopecia.
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Intolerant to daratumumab.
  • to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m\^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior .
  • Corneal epithelial disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Belantamab mafodotin and Bortezomib plus Dexamethasone

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Dexamethasone

  • Active comparator
    Daratumumab and Bortezomib plus Dexamethasone

    Drug: Daratumumab · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

  • Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody

  • Proteasome Inhibitor

  • Synthetic glucocorticoid with anti-tumor activity

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

    Time frame: Up to approximately 32 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as time from the date of randomization until the date of death due to any cause.

    Time frame: Up to 255 weeks

  2. Duration of Response (DoR)

    DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

    Time frame: Up to 255 weeks

  3. Minimal Residual Disease (MRD) Negativity Rate

    Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative by next generation sequencing (NGS).

    Time frame: Up to 255 weeks

  4. Complete Response Rate (CRR)

    CRR is defined as percentage of participants with a confirmed complete response (CR) or better (i.e., CR, stringent Complete Response (sCR)).

    Time frame: Up to 255 weeks

  5. Overall Response Rate (ORR)

    ORR is defined as percentage of participants with a confirmed partial response (PR) or better (i.e. PR, Very Good Partial Response \[VGPR\], CR or sCR).

    Time frame: Up to 255 weeks

  6. Clinical Benefit Rate (CBR)

    CBR is defined as percentage of participants with a confirmed minimal response (MR) or better per International Myeloma Working Group (IMWG).

    Time frame: Up to 255 weeks

  7. Time to Response (TTR)

    TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

    Time frame: Up to 255 weeks

  8. Time to Progression (TTP)

    TTP is defined as the time from the date of randomization until the earliest date of documented PD or death due to PD. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

    Time frame: Up to 255 weeks

  9. Progression-free Survival on Subsequent Line of Therapy (PFS2)

    PFS2 is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever is earlier. If disease progression after new anti-myeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier

    Time frame: Up to 255 weeks

  10. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

    Time frame: Up to 255 weeks

  11. Number of Participants With Clinically Significant Changes in Hematology Parameters

    Blood samples will be collected for the analysis of hematology parameters.

    Time frame: Up to 255 weeks

  12. Number of Participants With Clinically Significant Changes in Clinical Chemistry

    Blood samples will be collected for the analysis of clinical chemistry parameters.

    Time frame: Up to 255 weeks

  13. Number of Participants With Clinically Significant Changes in Urine Dipstick

    Urine samples will be collected for the urine dipstick analysis.

    Time frame: Up to 255 weeks

  14. Number of Participants With Abnormal Ocular Findings on Ophthalmic Examination

    Time frame: Up to 255 weeks

  15. Plasma Concentrations of Belantamab Mafodotin (Total Antibody)

    Blood samples will be collected for PK analysis of belantamab mafodotin.

    Time frame: Up to 255 weeks

  16. Plasma Concentrations of Belantamab Mafodotin (ADC)

    Blood samples will be collected for PK analysis of belantamab mafodotin.

    Time frame: Up to 255 weeks

  17. Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF)

    Blood samples will be collected for PK analysis of belantamab mafodotin.

    Time frame: Up to 255 weeks

  18. Number of Participants With Positive Anti-Drug Antibodies (ADAs) Against Belantamab Mafodotin

    Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

    Time frame: Up to 255 weeks

  19. Titers of ADAs Against Belantamab Mafodotin

    Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be further tested in screening assay, and positive samples will be further characterized for antibody titers.

    Time frame: Up to 255 weeks

  20. Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)

    The PRO-CTCAE is a patient-reported outcome measure that was developed to evaluate symptomatic toxicities in patients in cancer clinical trials; it characterizes the frequency, severity, interference, and presence or absence of symptomatic toxicities. Responses can range from 0 ("never," "none," "not at all," or "absent") to 4 ("almost constantly," "very severe," or "very much"), with a higher score indicating a higher frequency, severity, or interference of adverse events.

    Time frame: Up to 255 weeks

  21. Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)

    The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores are averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Up to 255 weeks

  22. Change From Baseline in HRQoL as Measured by EORTC IL52

    The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems.

    Time frame: Up to 255 weeks

07

Results

Posted Apr 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneBelantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + Dex
Started3240
Safety population3040
Completed00
Not completed3240
Withdrew: Death414
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject53
Withdrew: Physician decision01
Withdrew: Ongoing2321

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

Time frame:
Up to approximately 32 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsBelantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + Dex
Progression-free Survival (PFS)NA (20.2 to NA)8.4 (4.9 to 21.5)
Statistical analysis
  • Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) vs Daratumumab + Bor + Dex · Hazard ratio (hr): 0.24 · 95% CI 0.11 to 0.56Hazard ratio was estimated using a Cox Proportional Hazards model stratified by the number of lines of prior therapy, prior bortezomib and revised international staging system (R-ISS) at screening, with a covariate of treatment.
SecondaryOverall Survival (OS)

OS is defined as time from the date of randomization until the date of death due to any cause.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryDuration of Response (DoR)

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryMinimal Residual Disease (MRD) Negativity Rate

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative by next generation sequencing (NGS).

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryComplete Response Rate (CRR)

CRR is defined as percentage of participants with a confirmed complete response (CR) or better (i.e., CR, stringent Complete Response (sCR)).

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryOverall Response Rate (ORR)

ORR is defined as percentage of participants with a confirmed partial response (PR) or better (i.e. PR, Very Good Partial Response \[VGPR\], CR or sCR).

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate (CBR)

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better per International Myeloma Working Group (IMWG).

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryTime to Response (TTR)

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryTime to Progression (TTP)

TTP is defined as the time from the date of randomization until the earliest date of documented PD or death due to PD. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryProgression-free Survival on Subsequent Line of Therapy (PFS2)

PFS2 is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever is earlier. If disease progression after new anti-myeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA dictionary).

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Changes in Hematology Parameters

Blood samples will be collected for the analysis of hematology parameters.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Changes in Clinical Chemistry

Blood samples will be collected for the analysis of clinical chemistry parameters.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Changes in Urine Dipstick

Urine samples will be collected for the urine dipstick analysis.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Abnormal Ocular Findings on Ophthalmic Examination
Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryPlasma Concentrations of Belantamab Mafodotin (Total Antibody)

Blood samples will be collected for PK analysis of belantamab mafodotin.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryPlasma Concentrations of Belantamab Mafodotin (ADC)

Blood samples will be collected for PK analysis of belantamab mafodotin.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryPlasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF)

Blood samples will be collected for PK analysis of belantamab mafodotin.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Positive Anti-Drug Antibodies (ADAs) Against Belantamab Mafodotin

Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryTiters of ADAs Against Belantamab Mafodotin

Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be further tested in screening assay, and positive samples will be further characterized for antibody titers.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)

The PRO-CTCAE is a patient-reported outcome measure that was developed to evaluate symptomatic toxicities in patients in cancer clinical trials; it characterizes the frequency, severity, interference, and presence or absence of symptomatic toxicities. Responses can range from 0 ("never," "none," "not at all," or "absent") to 4 ("almost constantly," "very severe," or "very much"), with a higher score indicating a higher frequency, severity, or interference of adverse events.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryChange From Baseline in Health Related Quality of Life (HRQoL) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores are averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

SecondaryChange From Baseline in HRQoL as Measured by EORTC IL52

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems.

Time frame:
Up to 255 weeks

Results for this outcome have not been posted.

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to approximately 32 months. The results presented are until the primary completion date. Additional results will be provided within a year of study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)4/30 (13.3%)25/30 (83.3%)30/30 (100%)
Daratumumab + Bor + Dex14/40 (35%)27/40 (67.5%)39/40 (97.5%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventBelantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + Dex
PneumoniaInfections and infestations11/306/40
ThrombocytopeniaBlood and lymphatic system disorders9/307/40
Platelet count decreasedInvestigations7/305/40
CataractEye disorders3/300/40
Herpes zosterInfections and infestations2/302/40
Chronic kidney diseaseRenal and urinary disorders2/300/40
COVID-19Infections and infestations0/302/40
IleusGastrointestinal disorders0/302/40
GastroenteritisInfections and infestations1/301/40
Urinary tract infectionInfections and infestations1/300/40
Most frequent other events
Showing 10 of 120
Most frequent other events
EventBelantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + Dex
Platelet count decreasedInvestigations23/3027/40
AnaemiaBlood and lymphatic system disorders19/3029/40
PneumoniaInfections and infestations21/3014/40
Aspartate aminotransferase increasedInvestigations20/3015/40
HypokalaemiaMetabolism and nutrition disorders20/3023/40
White blood cell count decreasedInvestigations16/3026/40
Alanine aminotransferase increasedInvestigations19/3019/40
Lymphocyte count decreasedInvestigations13/3022/40
Neutrophil count decreasedInvestigations14/3020/40
ThrombocytopeniaBlood and lymphatic system disorders15/3013/40

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + DexTotal
Mean63.0 ± 9.3661.5 ± 8.9562.2 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + DexTotal
Female132033
Male192039
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + DexTotal
Hispanic or Latino000
Not Hispanic or Latino324072
Unknown or Not Reported000
08

Study locations

11 sites
  • GSK Investigational Site
    Beijing, China
  • GSK Investigational Site
    Changchun, China
  • GSK Investigational Site
    Guangzhou, China
  • GSK Investigational Site
    Hangzhou, China
  • GSK Investigational Site
    Jinan, China
  • GSK Investigational Site
    Nanjing, China
  • GSK Investigational Site
    Shenyang, China
  • GSK Investigational Site
    Suzhou, China
  • GSK Investigational Site
    Tianjin, China
  • GSK Investigational Site
    Wuhan, China
  • GSK Investigational Site
    Zhengzhou, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Apr 2024, 32 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 32 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 11, 2025
StartActual
Jul 28, 2021
Primary completionActual
Apr 3, 2024
CompletionEst.
Jun 30, 2028
Results first posted
Apr 23, 2025
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06868654
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Jul 28, 2021
Primary completion
Apr 3, 2024
Completion
Jun 30, 2028 (estimated)
Results posted
Apr 23, 2025
Last update
Apr 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion